MYGN

Company Overview — What Does MYRIAD GENETICS INC Do?

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. MYRIAD GENETICS INC (MYGN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Paul J. Diaz and employs approximately 2,600 people, headquartered in SALT LAKE CITY, Utah. With a market capitalization of $429M, MYGN is one of the notable companies in the Healthcare sector.

MYRIAD GENETICS INC (MYGN) Stock Rating — Reduce (April 2026)

As of April 2026, MYRIAD GENETICS INC receives a Reduce rating with a composite score of 28.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MYGN ranks #3,745 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MYRIAD GENETICS INC ranks #629 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MYGN Stock Price and 52-Week Range

MYRIAD GENETICS INC (MYGN) currently trades at $4.35. The stock lost $0.09 (2.0%) in the most recent trading session. The 52-week high for MYGN is $10.30, which means the stock is currently trading -57.8% from its annual peak. The 52-week low is $3.76, putting the stock 15.7% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is MYGN Overvalued or Undervalued? — Valuation Analysis

MYRIAD GENETICS INC (MYGN) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.20x, versus the sector average of 2.75x. The price-to-sales ratio is 0.54x, compared to 1.66x for the average Healthcare stock.

At current multiples, MYRIAD GENETICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MYRIAD GENETICS INC Profitability — ROE, Margins, and Quality Score

MYRIAD GENETICS INC (MYGN) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -103.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.8% versus the sector average of -33.1%.

On a margin basis, MYRIAD GENETICS INC reports gross margins of 70.0%, compared to 71.5% for the sector. The operating margin is -47.5% (sector: -66.1%). Net profit margin stands at -44.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -2.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MYGN Debt, Balance Sheet, and Financial Health

MYRIAD GENETICS INC has a debt-to-equity ratio of 33.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.49x, indicating strong short-term liquidity. Total debt on the balance sheet is $120M. Cash and equivalents stand at $145M.

MYGN has a beta of 1.24, meaning it is more volatile than the broader market — a $10,000 investment in MYGN would be expected to move 24.4% more than the S&P 500 on any given day. The stability factor score for MYRIAD GENETICS INC is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MYRIAD GENETICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, MYRIAD GENETICS INC reported revenue of $828M and earnings per share (EPS) of $-3.95. Net income for the quarter was $-380M. Gross margin was 70.0%. Operating income came in at $-402M.

In FY 2025, MYRIAD GENETICS INC reported revenue of $825M and earnings per share (EPS) of $-3.95. Net income for the quarter was $-366M. Gross margin was 69.9%. Revenue grew -1.6% year-over-year compared to FY 2024. Operating income came in at $-387M.

In Q3 2025, MYRIAD GENETICS INC reported revenue of $206M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-27M. Gross margin was 69.9%. Revenue grew -3.6% year-over-year compared to Q3 2024. Operating income came in at $-23M.

In Q2 2025, MYRIAD GENETICS INC reported revenue of $213M and earnings per share (EPS) of $-3.57. Net income for the quarter was $-331M. Gross margin was 71.2%. Revenue grew 0.8% year-over-year compared to Q2 2024. Operating income came in at $-329M.

Over the past 8 quarters, MYRIAD GENETICS INC has demonstrated a growth trajectory, with revenue expanding from $212M to $828M. Investors analyzing MYGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MYGN Dividend Yield and Income Analysis

MYRIAD GENETICS INC (MYGN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MYGN Momentum and Technical Analysis Profile

MYRIAD GENETICS INC (MYGN) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

MYGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MYRIAD GENETICS INC (MYGN) ranks #629 out of 838 stocks based on the Blank Capital composite score. This places MYGN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MYGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MYGN vs S&P 500 (SPY) comparison to assess how MYRIAD GENETICS INC stacks up against the broader market across all factor dimensions.

MYGN Next Earnings Date

No upcoming earnings date has been announced for MYRIAD GENETICS INC (MYGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MYGN? — Investment Thesis Summary

The quantitative profile for MYRIAD GENETICS INC suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, MYRIAD GENETICS INC (MYGN) earns a Reduce rating with a composite score of 28.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MYGN stock.

Related Resources for MYGN Investors

Explore more research and tools: MYGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MYGN head-to-head with peers: MYGN vs AZN, MYGN vs SLGL, MYGN vs VMD.